Supramolecular Heterodimer Peptides Assembly for Nanoparticles Functionalization

Nanoparticle (NP) surface functionalization with proteins, including monoclonal antibodies (mAbs), mAb fragments, and various peptides, has emerged as a promising strategy to enhance tumor targeting specificity and immune cell interaction. However, these methods often rely on complex chemistry and s...

Full description

Saved in:
Bibliographic Details
Published in:Advanced healthcare materials 2024-06, Vol.13 (15), p.e2304250-n/a
Main Authors: Mathieu, Clélia, Ghosh, Shayamita, Draussin, Julien, Gasser, Adeline, Jacquot, Guillaume, Banerjee, Mainak, Gupta, Tanushree, Schmutz, Marc, Mirjolet, Céline, Tillement, Olivier, Lux, François, Klymchenko, Andrey S., Donzeau, Mariel, Pivot, Xavier, Harlepp, Sébastien, Detappe, Alexandre
Format: Article
Language:English
Subjects:
Antigen (tumor-associated)
Antigens
Assembly
auto‐assembly
biofunctionalization
Breast cancer
CD38 antigen
ErbB-2 protein
Immune system
In vivo methods and tests
Monoclonal antibodies
Multiple myeloma
nanomedicine
Nanoparticles
Natural killer cells
peptide
Peptides
Physics
Polylactide-co-glycolide
Proteins
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nanoparticle (NP) surface functionalization with proteins, including monoclonal antibodies (mAbs), mAb fragments, and various peptides, has emerged as a promising strategy to enhance tumor targeting specificity and immune cell interaction. However, these methods often rely on complex chemistry and suffer from batch‐dependent outcomes, primarily due to limited control over the protein orientation and quantity on NP surfaces. To address these challenges, a novel approach based on the supramolecular assembly of two peptides is presented to create a heterotetramer displaying VHHs on NP surfaces. This approach effectively targets both tumor‐associated antigens (TAAs) and immune cell‐associated antigens. In vitro experiments showcase its versatility, as various NP types are biofunctionalized, including liposomes, PLGA NPs, and ultrasmall silica‐based NPs, and the VHHs targeting of known TAAs (HER2 for breast cancer, CD38 for multiple myeloma), and an immune cell antigen (NKG2D for natural killer (NK) cells) is evaluated. In in vivo studies using a HER2+ breast cancer mouse model, the approach demonstrates enhanced tumor uptake, retention, and penetration compared to the behavior of nontargeted analogs, affirming its potential for diverse applications. A versatile platform of nanoparticles is developed that is functionalized through the supramolecular assembly of peptides, designed to selectively bind to tumoral or immune receptors. In vitro, the versatility of the approach using various nanoparticles and targeting different receptors is demonstrated. The in vivo study has specifically concentrated on HER2+ tumors, confirming the successful delivery of these targeted‐nanoparticles.
ISSN:2192-2640
2192-2659
2192-2659
DOI:10.1002/adhm.202304250